Mindray Medical International Limited

Third Quarter 2007

1

Disclaimer

This material contains forward-looking statements with respect to the company's outlook regarding drivers, developments, and trends affecting its worldwide markets, opening of international offices, new product development and commercial launch dates, projected revenues, net income margins, earnings per share, revenue growth targets, net income growth targets, sales force and distributor targets, projections of the size of China's healthcare market, estimated government expenditures, research and development expenditure targets, the company's manufacturing development plan, and the anticipated results of its product development activities. These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Factors that affect the Company's business operations and product development, as well as a further list and description of risks and uncertainties associated with Mindray's business, are discussed in its reports filed with the Securities and Exchange Commission, including its most recent annual report on Form 20-F. Mindray disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2

Mission and Vision

To improve the health and well-being of the world’s people by providing thehighest quality medical equipment and services at the most competitive prices

MISSION VISIONTo be a world-class medical equipment solutions provider by increasing accessibility to affordable quality health care while creating value for customers, employees, shareholders and society

3

Company Snapshot

Founded in 1991 in Shenzhen, China - 29 offices in China, 11 international offices

More than 3,700 employees worldwide

World-class R&D platform with largest R&D team in China and a research center in Seattle, USA

Leading market position in China29 sales and service offices in major cities throughout China850 sales and sales support staffOver 2,000 distributors including nearly 900 exclusive distributors

Established and rapidly growing presence abroadSales in more than 140 countriesMore than 1,200 international distributors

Founded in 1991 in Shenzhen, China - 29 offices in China, 11 international offices

More than 3,700 employees worldwide

World-class R&D platform with largest R&D team in China and a research center in Seattle, USA

Leading market position in China29 sales and service offices in major cities throughout China850 sales and sales support staffOver 2,000 distributors including nearly 900 exclusive distributors

Established and rapidly growing presence abroadSales in more than 140 countriesMore than 1,200 international distributors

4

Product Lines

Diagnostic imaging systems• B/W ultrasound• Color Ultrasound• Digital radiography• 10+ models

In-Vitro diagnostic products• 3 part hematology• Biochemistry• 5 part hematology• 10+ models• 30 hematology reagents and 35 biochemistry reagent

Patient monitoring & life support products• Patient monitoring devices• Anesthesia Machines• Defibrillators• 20+ models

5

2335

89

13

5329.7%

27.5%

25.6%26.0%22.0%20

40

60

80

100

2003 2004 2005 2006 2007E0%

25%

50%

75%

100%

300

59

19489 138

54.6% 54.3% 54.3% 54.3%

04080

120160200240280

2003 2004 2005 2006 2007E0%

25%

50%

75%

100%

Solid Financial Profile

Revenue BreakdownRevenue BreakdownNet Revenue1Net Revenue1

Gross margin(US$mm)

Net Income1,2Net Income1,2

1 Foreign exchange rate: using the noon buying rate of the Federal Reserve of New York at the quarter/year end 2 Non-GAAP net income excluding impact from share-based compensation, amortization/expense of acquired intangibles (net of tax impact)

CAGR = 49%

(US$mm) Net Margin

CAGR = 58%

Diagnostic30.8%

PMD38.6%

Ultrasound29.1%

Other1.5%

North America8.0%

Europe17.0%

Other11.6%

China49.8%

Other Asia13.5%

Jan-Sep07 Geographic Breakdown

Jan-Sep07 Segment Breakdown

6

2007 Achievements

Achieved robust top- and bottom-line growthNet revenues in the range of RMB2,180 to 2,200 million, a 43.9% or 45.2% YoY growth

Net income in the range of RMB 640 to 660 million, a 53.6% or 58.3% YoY growth

Leveraged our leading market position in ChinaExpanded No. 1 market share position in existing product segments

No. 1 domestic player in 5-part hematology analyzers and color ultrasound imaging systems

Enhanced international presenceAchieved more than 50% growth rate (60%+ in constant dollar terms) in international markets

Opened six more international offices in 2007

Expanded current product offerings to broaden market reachLaunched seven new products

Entered into a new product segment – Digital Radiography

Maintained a disciplined cost focus

Achieved robust top- and bottom-line growthNet revenues in the range of RMB2,180 to 2,200 million, a 43.9% or 45.2% YoY growth

Net income in the range of RMB 640 to 660 million, a 53.6% or 58.3% YoY growth

Leveraged our leading market position in ChinaExpanded No. 1 market share position in existing product segments

No. 1 domestic player in 5-part hematology analyzers and color ultrasound imaging systems

Enhanced international presenceAchieved more than 50% growth rate (60%+ in constant dollar terms) in international markets

Opened six more international offices in 2007

Expanded current product offerings to broaden market reachLaunched seven new products

Entered into a new product segment – Digital Radiography

Maintained a disciplined cost focus

7

Leading Market Position in China

More than 80% of our sales are through distributorsMore than 80% of our sales are through distributors Competitive Price to Performance Ratio

Around 30% discount vs. international players20% premium vs. domestic players

Extensive Sales Network29 sales and sales support offices800+ sales and service staff2,000+ distributors (incl. over 800+ exclusive distributors

Sales Force ManagementLow employee turnover rate 200+ experienced sales employees

Strong Brand Recognition Brand loyalty – recognized domestic hospitals across ChinaHigh-quality products and customer support services

Competitive Price to Performance Ratio

Around 30% discount vs. international players20% premium vs. domestic players

Extensive Sales Network29 sales and sales support offices800+ sales and service staff2,000+ distributors (incl. over 800+ exclusive distributors

Sales Force ManagementLow employee turnover rate 200+ experienced sales employees

Strong Brand Recognition Brand loyalty – recognized domestic hospitals across ChinaHigh-quality products and customer support services

Urumchi

Shenyang

DalianBeijing

QingdaoJinan

Taiyuan

Zhengzhou

Xi’an

Lanzhou

ShanghaiNanjing

Hangzhou

Fuzhou

HefeiWuhan

NanchangChangsha

Guangzhou

Hong Kong

ShenzhenNanning

Chengdu

Chongqing

Kunming

Guiyang

Changchun

Shijiazhuang

8

Forecast incremental demand by 2020 Forecast incremental demand by 2020 Chinese public health marketChinese public health market

Source: China Statistical Yearbook 2006, Bear Sterns Asia Ltd. estimates

Source: Goldman Sachs Research, Gao Hua Securities Research estimates

0

500

1000

1500

2000

2500

1998

1999

2000

2001

2002

2003

2004

E2005

E2006

E2007

E2008

E2009

E2010

Government Bugdetary Expenditure Social ExpenditureResident Individual Expenditure

RMB billion

CAGR 12.7%

CAGR 20.1%

40 108 185 296 365

1914

246

776

73 108 139

794

0

500

1000

1500

2000

2500

India China U K Germany Japan U S

2005 Spending Incremental Demand by 2020

Growth Catalysts in China---Macro Environment

Healthcare expenditures as % GDPHealthcare expenditures as % GDP10,948.6

1,757.6 1,417.0600.6 432.9 208.3

5,711

2,428 2,981

61 240.41,794.9

3016727257

8.0%

10.1%

5.6%

7.6%

4.1%5.6%

3.1%

15.2%

US UK FR CN TR IN RU ID

GDP(US$ billion)Healthcare expenditure per capita(US$)% of GDP used for healthcare expenditure

Source: WHO and National Bureau of Statistics of China, 2003

By 2020 $US776 bn of incremental

demand will come from China

Hea

lthc

are

spen

ding

(U

S$ b

n)

9

Gain market share in high-end markets Further penetrate high-end patient monitoring market with Beneview Series products

5-Part Hematology Analyzer – newly released, significant market potential

Target rural area hospitals and community clinicsDC3 Color Ultrasound

—First color ultrasound targeted rural hospitals—Strong government tender potential

BS-120: Replacement for semi-auto bio-chemistry analyzer

Introduce new products to penetrate new marketsAnesthesia Machine– new product segment, significant market potential

Digital Radiography

Biochemistry analyzers with speed of 400 tests per hour

Generate more recurring revenue from reagentsWide installation base of 3-part hematology analyzers

More biochemistry reagents launched into market

Enhance brand recognition Differentiate from domestic peers by branding

Gain market share in high-end markets Further penetrate high-end patient monitoring market with Beneview Series products

5-Part Hematology Analyzer – newly released, significant market potential

Target rural area hospitals and community clinicsDC3 Color Ultrasound

—First color ultrasound targeted rural hospitals—Strong government tender potential

BS-120: Replacement for semi-auto bio-chemistry analyzer

Introduce new products to penetrate new marketsAnesthesia Machine– new product segment, significant market potential

Digital Radiography

Biochemistry analyzers with speed of 400 tests per hour

Generate more recurring revenue from reagentsWide installation base of 3-part hematology analyzers

More biochemistry reagents launched into market

Enhance brand recognition Differentiate from domestic peers by branding

2008 Growth Strategy in China

10

Revenue Breakdown by RegionRevenue Breakdown by Region

2003 Total Revenues: RMB 460million

(US$56mm)

Jan-Sept / 2007Total Revenues:

RMB 1,557 million(US$208mm)

Other11.6%

NorthAmerica

8.0%

Europe17.0%

OtherAsia13.5%

China49.8%

2003 – 2006 CAGR2003 – 2006 CAGR

America

103.8% 87.3%50.5% 31.0% 48.8%

Other Asia Europe Other North China Total

Rapidly Expanding International Presence

Other3.1%

NorthAmerica

7.7%Europe6.7%

OtherAsia7.3%

China75.2%

112.9%

11

Growth Catalysts in International Markets

Aging Population (More Patients)

Developed Countries (North America, Western Europe and Japan)Cost-cutting healthcare reformDoctor/Nursing - staff shortagesExpansion in clinical application

Emerging Markets (BRICs, VISTA, Eastern Europe, Mexico)Increased disease awarenessBetter affordability

Expansion to other product areas such as DR and defibrillators

Aging Population (More Patients)

Developed Countries (North America, Western Europe and Japan)Cost-cutting healthcare reformDoctor/Nursing - staff shortagesExpansion in clinical application

Emerging Markets (BRICs, VISTA, Eastern Europe, Mexico)Increased disease awarenessBetter affordability

Expansion to other product areas such as DR and defibrillators

12

Strategy for International Expansion

AMERICA EUROPE ASIA-PACIFICAFRICA

Vancouver

Mexico City

Indonesia

Amsterdam

Moscow

Istanbul

Mumbai

SeattleBoston

Toronto

Sao Paulo

Global HQ in

Shenzhen

30 Offices in China

Current Offices

Opening Soon

London

France

Open more overseas offices

Localization

Expand and optimize distribution and service network

Enhance brand awareness

13

Patents

Authorized (in China): 212

Pending (in China): 484

Pending (in USA): 107

Others8.0%

Mechanic11.0%

System16.0%

Testing8.0%

Software33.0%

Hardware24.0%

PhD2.8%Others

7.4% Bachelor42.2%

Master47.6%

Total: 1,036 Engineers

Note: As of April 30, 2007

Degree Functionality

1.63.0

4.8

7.4

13.2

19.1

28.0

6.6%

8.1%8.6% 8.8%

9.8% 9.8%

10.6%

0.0

5.0

10.0

15.0

20.0

25.0

30.0

2001 2002 2003 2004 2005 2006 2007E0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

R&D InvestmentR&D Investment

Note: GAAP R&D investment as percentage of sales is 8.8% in 2004, 9.6% in 2005 and 9.4% in 2006

(US$mm) % of sales (%)

R&D Headcount R&D Headcount

R&D StructureR&D Structure PatentsPatents

Proven R&D Capabilities

Over 1,000 staffOver 1,000 staff

700 719

1036

154 188283

472

246189 207

288200 208

217

145 155

258

150 149

2001 2002 2003 2004 2005 2006 2007

R&D Team Size

PMDDiagnostic

Ultrasound

Others

14

3-part Hematology

Patient Monitoring

Devices

Anesthesia Machines

Addr

essa

ble

Mar

ket

New Product Pipeline

Patient Monitoring & Life Support ProductsPatient Monitoring & Life Support Products

In-Vitro Diagnostic ProductsIn-Vitro Diagnostic Products Diagnostic Imaging SystemsDiagnostic Imaging Systems

Time

Immunoassay

Addr

essa

ble

Mar

ket

3-Part Hematology

5-Part Hematology

Biochemistry

Addr

essa

ble

Mar

ket

B/W Ultrasound

Digital Radiography

Time

Other Imaging Products

Color Ultrasound

Defibrillator & Surgical beds and lights

iPM Monitor(4Q, 2008)

Time

Defibrillator(4Q 2008)

BC-5300/5380 5-PartHematology Analyzer(1Q, 2008)

BS-380 Biochemistry Analyzer(4Q 2008)

6 Reagents(1Q 2008)

DC-3 Ultrasound (1Q 2008)

DC-7 Ultrasound (4Q 2008)

DR-50 Digital Radiography(2Q 2008)

DR-51(4Q 2008)

New Products in 2008

15

54.3% 54.3%54.7%

54.3%

56.7%

55.0%

52%

53%

54%

55%

56%

57%

58%

2003

2004

2005

2006

1-9/20

06

1-9/20

07

* Non- GAAP

Maintain Sustainable Cost Advantage

Maintain a consistent gross margin of 54~56% during the past 4 years

R&D lowers costs and pushes products up the value chain

R&D working together with manufacturing to deliver competitive cost advantage

Further increase our operational efficiencies as we build economies of scale

Consolidated Gross Margin * (%)Consolidated Gross Margin * (%)

16

Summary

Mindray’s mission to provide high-quality medical devices at affordable prices has proven to deliver high-growth in both developed and developing markets

Pragmatic positioning in each market and segment optimizes earnings by striking a balance between profit and market share

World-class R&D capabilities and operational efficiency ensures quality consistency, pricing competitiveness and abundant cash flow

Diversified product portfolio and geographic distribution reduces earnings fluctuations and maximizes exposure to growth opportunities across segments and geographies

17

Thank you!

Q&A

18

Emperor4.5%

Landwind3.3%

Zhonghui6.2%

Well2.7%

Toshiba5.3%Hitachi

1.9%

Teknova3.5%

Other4.8%

Aloka9.0%

Siemens4.5%

Medison2.3%

GE14.3%

SIUI5.6%Chinson

4.0%

Mindray28.1%

Procan2.1%

Other Imported8.6%

NK3.9%

Other Domestic5.6%

Biote3.4%

Sysmex14.2%

Tecom11.2%

Botest5.6%

Perlong3.0%

Mindray42.4%

Transasia3.0%

Toshiba8.2%

Hitachi16.0%

Glamour3%

Other15.3%

Sinnowa1.7%

Olympus11.3%

Beckman5.4%

Vitalab3.2%

Sysmex4.1%

Mindray28.4%

And Leading Market Positions in China

Other Domestic5.9%SH Likang

3.2%

Philips18.1%

GE13.5%

Goldway3.3%BLT

1.6%

Gotom2.7%

Other Imported2.9%

Drager3.7%

Spacelabs2.0%

NK3.5%

Mindray39.9%

RMB 1,025mm

RMB 465mm

Patient Monitor DevicesPatient Monitor Devices

3-Part Hematology Analyzer3-Part Hematology Analyzer

200~400 T/H Biochemistry Analyzer200~400 T/H Biochemistry Analyzer

RMB 590mm

Source: Company Estimates

RMB: 693mm

B/W UltrasoundB/W Ultrasound

19

Other2.5%

Tearson1.0%

Neusoft1.7%

Aloka9.1%

Esaote5.9%

SonoScape1.4%

Medison4.3% Hitachi

4.0%

Toshiba5.4%

Philips20.3%

Siemens10.4%

Mindray4.7%Sysmex

33.9%

Other5.0%

NK8.9%

Bayer3.7%

Abbott8.6%

ABX7.6%

Coulter18.3%

Mindray14.0%

New Growth Areas in China

百思8.8%

航天长峰6.4%

Other4.3%

江苏凯泰5.7% 晨伟

2.8%无锡中原5.7%

Drager21.3%

谊安18.2%

GE22.8%

Mindray4.0%

RMB 301mm

5-Part Hematology Analyzer5-Part Hematology Analyzer

Source: Company Estimates

RMB 2,560mm

Color UltrasoundColor Ultrasound

RMB 703mm

Anesthesia MachineAnesthesia Machine

GE29.7%

Biochemistry AnalyzerBiochemistry Analyzer

Toshiba6.9%

Roche6.5%

Other19.0%

Abbott3.3%

Sysmex2.1%

Sinnowa4.3%

Olympus14.5%

Beckman10.9%

Hitachi17.7%

Mindray14.8%

RMB 1,078mm

20

Appendix: Excellent Financial Trajectory

50%

41%

55%52%50%

0%

10%

20%

30%

40%

50%

60%

2003 2004 2005 2006 2007YTD

Revenue Growth

55%

50%

41%

52%50%

0%

10%

20%

30%

40%

50%

60%

2003 2004 2005 2006 2007YTD

Growth of Income before Taxes & MI*

1.22

2.46

3.16

5.71

4.33

0.0

1.0

2.0

3.0

4.0

5.0

6.0

2003 2004 2005 2006 2007E

EPS*

138

295

472

252

99

0

50

100

150

200

250

300

350

400

450

500

2003 2004 2005 2006 2007YTD

Free Cash Flow

(RM

B)

(RM

B m

illio

ns)

* Non-GAAP; 2007YTD using unaudited data as of September 30, 2007; 2007E data using mid-point of the latest 2007 guidance

21

Prudent Working Capital Management

222119

17

0

5

10

15

20

25

2004 2005 2006 3Q07

Accounts Receivable

64

6071

87

0

10

20

30

40

50

60

70

80

90

100

2004 2005 2006 3Q07

Inventory Days

57

38

3527

0

10

20

30

40

50

60

2004 2005 2006 3Q07

Accounts Payable

166

363

545

418

0

100

200

300

400

500

600

700

2004 2005 2006 2007YTD

Operating Cash Flow

(Day

s)

(Day

s)(D

ays)

(RM

B m

m)

22

Financials -- 3Q2007 Results Highlights

1 Non-GAAP figures excluding impact from share-based compensation expenses and amortization of intangibles

5964Inventory Days

Y/Y (%)Q/Q (%)3Q06(RMB)

2Q07(RMB)

3Q07(RMB) ( US$)(in millions)

100106201361

5757A/P Days

2122A/R Days2,3893422,562Total Shareholder’s Equity

44855413Total Liabilities19827199Inventories15619145Account Receivables

1,6201761,318Cash and Cash Equivalents

72%-2%17523172Net Income1

63%-5%18223173Operating Income160%0%32043321Gross Profit1

59%2%56277573Net Revenues

23

Financials – 3Q07 Results Highlights

Summary

Net sales increased 58.9% YOY

Non-GAAP gross margin was 56.0% in 3Q07 compared to 57% in 2Q07

70.0% increase YOY in net income (71.5% YOY increase in non-GAAP net income)

Cash & cash equivalents was US$232 million as of Sep. 30, 2007

Accounts receivable, 22 days and inventory, 64 days

24

Stable Margins and Disciplined Investment

56.0 55.8 54.757.0

3Q07 3Q06 2Q07 2006

Gross Margin (%)• Stable

margins• New

products drive slight gross margin expansion

R&D % of Sales (%)• Goal to

invest 10% of sales in R&D activities

G&A % of Sales (%)• Likely to be

lower than 4% in 2007

Selling % of Sales (%)• Increasing

investment in overseas sales & distribution networks

** Non-GAAP margins excluding impact from share-based compensation, amortization/expense of acquired intangibles (net of tax impact)

9.2 9.4 9.48.1

3Q07 3Q06 2Q07 2006

13.7 13.1 13.613.5

3Q07 3Q06 2Q07 2006

3.0 3.9 4.22.9

3Q07 3Q06 2Q07 2006

25

Manufacturing Expansion Plans

Operational in 2010

Operational in 2009，Focused on Producing Fundamental Parts for Products

Operational in 2008（Product assembly, Mechanical Machining, PCBA and Medical Accessories)Focus on Product Assembly and Medical Accessories after 2009

Operational in 2H 2008，Focused on Producing Reagents

Role and Configuration

240,000E

200,000E

75,000

21,000

Square Meters

Reagents(Hematology, Bio-chemistryRadioactive Immures)

Hong Hua Ling

Operation Lighting, Tables and Medical Imaging

NanJing JiangNing

Mechanical Machining, Plate Metal Machining, Plastic module and PCBA

Long Gang

Primary Products(Patient Monitors,Hematology Analyzers, etc), medical consumables and key accessories

Bai Wang Xin

ProductsFacility Location